Back to Search
Start Over
Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Source :
- Acta Clinica Belgica. 74:439-444
- Publication Year :
- 2018
- Publisher :
- Informa UK Limited, 2018.
-
Abstract
- Objectives: Disease progression in metastatic castration-resistant prostate cancer (mCRPC) is dependent on androgen signaling. This case describes the complex adaptive androgen signaling mechanisms...
- Subjects :
- Male
Drug-Related Side Effects and Adverse Reactions
medicine.drug_class
Abiraterone Acetate
Antineoplastic Agents
Bone Neoplasms
Spironolactone
urologic and male genital diseases
03 medical and health sciences
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
Carcinoma
medicine
Humans
Enzalutamide
Drug Interactions
030212 general & internal medicine
Mineralocorticoid Receptor Antagonists
Neoplasm Staging
Aged, 80 and over
business.industry
Contraindications, Drug
General Medicine
medicine.disease
Androgen
Eplerenone
Androgen receptor
Prostatic Neoplasms, Castration-Resistant
Abiraterone
Treatment Outcome
Withholding Treatment
chemistry
030220 oncology & carcinogenesis
Disease Progression
Cancer research
business
medicine.drug
Subjects
Details
- ISSN :
- 22953337 and 17843286
- Volume :
- 74
- Database :
- OpenAIRE
- Journal :
- Acta Clinica Belgica
- Accession number :
- edsair.doi.dedup.....27b717150dd1dd649c50d633d341c7d3
- Full Text :
- https://doi.org/10.1080/17843286.2018.1543827